Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Bezpečnost a účinnost zařízení ENTERPRISE 2 v endovaskulární léčbě intrakraniálních aneuryzmat (EMPOWER)

2. listopadu 2026 aktualizováno: Medos International SARL

Registr zařízení pro cévní rekonstrukci a zaváděcího systému ENTERPRISE 2: Multicentrická, prospektivní, jednoramenná observační studie k vyhodnocení bezpečnosti a účinnosti zařízení k usnadnění embolizace intrakraniálních aneuryzmat endovaskulární spirálou

The study is designed to evaluate the safety and effectiveness of ENTERPRISE 2 vascular reconstruction device and delivery system (hereinafter referred to as ENTERPRISE 2) to facilitate endovascular coil embolization of intracranial aneurysms.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

This is a prospective, multicenter, single-arm observational study, in which enrolled patients will be implanted with the ENTERPRISE 2 for evaluation of safety and effectiveness of ENTERPRISE 2 in real-world applications.

The study population will consist of 164 patients with ruptured or unruptured intracranial aneurysms and a parent vessel diameter of ≥2.5 mm and ≤4 mm. All patients will be implanted with the study device.

The enrolled patients will be followed at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure.

The primary endpoint is the incidence of aneurysm recanalization (at 180 days) evaluated through digital subtraction angiography (DSA). Secondary effectiveness endpoints include incidence of aneurysm recanalization (at 1 year), successful stent/coil placement rate (immediately post procedure), aneurysm occlusion (immediately post procedure, at 180 days and 1 year), incidence of retreatment (at 30 and 180 days, and 1, 2, 3, 4 and 5 years). Safety evaluation include: incidence of disabling stroke or neurological death (at 180 days and 1 year), incidence of in-stent thrombosis (at 180 days and 1 year), and incidence of in-stent stenosis (at 180 days and 1 year). Exploratory endpoints include stent wall apposition performance (intra-procedure), first-time deployment success rate (intra-procedure) and duration of stent deployment (intra-procedure).

Typ studie

Pozorovací

Zápis (Aktuální)

164

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Beijing Municipality
      • Beijing, Beijing Municipality, Čína, 100070
        • Beijing Tiantan Hospital, Capital Medical University
      • Beijing, Beijing Municipality, Čína, 100029
        • Beijing Anzhen Hospital, Capital Medical University
    • Guangdong
      • Guangzhou, Guangdong, Čína
        • Zhujiang Hospital of Southern Medical University
    • Henan
      • Zhengzhou, Henan, Čína, 450052
        • The first affiliated hospital of Zhengzhou university
    • Hubei
      • Wuhan, Hubei, Čína, 430022
        • Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
    • Jiangsu
      • Nanjing, Jiangsu, Čína, 210008
        • Nanjing Drum Tower Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Čína, 330006
        • The first affiliated hospital of Nanchang university
    • Liaoning
      • Shenyang, Liaoning, Čína, 110004
        • Shengjing Hospital of China Medical University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Čína
        • Huashan Hospital Shanghai Medical college, Fudan University
    • Zhejiang
      • Hangzhou, Zhejiang, Čína, 310007
        • Zhejiang Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 80 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Ukázka pravděpodobnosti

Studijní populace

This study will be conducted in patients with unruptured or ruptured intracranial aneurysm with a parent vessel diameter of ≥2.5 mm and ≤4 mm.

Popis

Inclusion Criteria:

  1. Patient (or his/her legal representative) understands the nature of the procedure and provides voluntary written informed consent for the use of his/her peri-procedural and follow-up data;
  2. Aged between 18 years and 80 years of age the time of consent;
  3. Patient has been diagnosed with ruptured (Hunt-Hess Grade I-III) or unruptured intracranial aneurysm and requires the endovascular treatment;
  4. Parent vessel with a diameter of ≥2.5 mm and ≤4 mm;
  5. Patient is willing to return to the investigational site for the post-procedure follow-up evaluations.

Exclusion Criteria:

  1. Severe co-morbidity associated with a life-expectancy of less than twelve months as determined by the investigator;
  2. Poor clinical condition with modified Rankin Scale (mRS) score ≥4;
  3. Having prior or potential severe allergic reaction to contrast medium;
  4. Known allergies to any of the device components, including Enterprise 2 and PROWLER® SELECT™ Plus Infusion Catheter;
  5. Angiogram demonstrating that the aneurysm is not appropriate for endovascular treatment (i.e. severe intracranial vessel tortuosity, stenosis, intracranial vasospasm not responsive to medical therapy);
  6. Arteriovenous malformation (AVM) in the territory of the target aneurysm;
  7. Unsuitable for the antithrombotic and/or anticoagulant therapies;
  8. Implantation of an intracranial stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
  9. Implantation of a carotid stent associated with aneurysm or symptom distribution within 12 weeks prior to signature of Informed Consent Form;
  10. Evidence of active infection;
  11. Pregnant or lactating women;
  12. Having participated in clinical studies of other investigational drugs or devices within 30 days prior to signature of Informed Consent Form, excluding epidemiological studies of observational nature or natural history or not involving intervention;
  13. Pre-planned staged procedure of target aneurysms.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
ENTERPRISE 2 group

The study population enrolled for this clinical study is "aneurysm patients who need stent-assisted coiling treatment", using ENTERPRISE 2 device.

The ENTERPRISE 2 Vascular Reconstruction Device is intended for use with occlusive devices in the treatment of intracranial aneurysms.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of aneurysm recanalization
Časové okno: at 180 days post procedure

Incidence of aneurysm recanalization (at 180 days) = number of target aneurysm recanalization (at 180 days) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 180-day follow-up will be obtained through DSA, and the post-procedure immediate aneurysm recanalization shown in angiograms will be graded as per the Raymond-Roy Classification Scale.

The Raymond-Roy Classification at each follow-up time point increased by ≥ one class relative to that immediately after the procedure is defined as recanalization (e.g., Class I immediately after the procedure, Class II at 180-day follow-up).

at 180 days post procedure

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of aneurysm recanalization
Časové okno: at 1 year post procedure

Incidence of aneurysm recanalization (at 1 year) = number of target aneurysm recanalization (at 1 year) ÷ total number of target aneurysms receiving follow-up × 100%. The results of aneurysm angiography at 1 year follow-ups will be obtained through DSA or MRA or CTA.

at 1 year post procedure
Successful stent/coil placement rate
Časové okno: immediately post procedure

Successful stent/coil placement rate = number of target aneurysms with successful stent/coil placement ÷ total number of target aneurysms× 100%.

Successful stent/coil placement is defined as successful stent deployment and successful delivery and placement of the coil at the target aneurysm assessed immediately post procedure through angiography.

immediately post procedure
Aneurysm occlusion
Časové okno: immediately post procedure, at 180 days and at 1 year post procedure

Aneurysm occlusion rate = number of target aneurysms with Raymond-Roy Class I or II aneurysm occlusion÷ total number of target aneurysms× 100%.

The aneurysm occlusion will be assessed by classifying the post-procedure immediate aneurysm occlusion shown in angiograms based on the Raymond-Roy Classification.

immediately post procedure, at 180 days and at 1 year post procedure
Incidence of retreatment
Časové okno: at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure

Incidence of retreatment = number of target aneurysms receiving retreatment during the follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

Retreatment refers to any intervention to the target aneurysm after completing first stent-assisted coil embolization for the target aneurysm.

at 30 days, 180 days, 1 year, 2 years, 3 years, 4 years and 5 years post procedure

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of disabling stroke or neurological death
Časové okno: at 180 days, at 1 year post procedure

Incidence of disabling stroke or neurological death = number of patients with disabling stroke or neurological death ÷ total number of patients receiving follow-up × 100%.

Stroke is defined as rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke or hemorrhagic stroke (i.e., intraparenchymal hemorrhage (IPH), SAH, subdural hemorrhage (SDH), epidural hemorrhage (EDH)).

Disabling stroke is defined as mRS score ≥ 3 assessed at a minimum of 90 days (+/- 30 days) post-stroke event.

Neurological death, also called brain death, refers to irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe.

at 180 days, at 1 year post procedure
Incidence of in-stent thrombosis
Časové okno: at 180 days, at 1 year post procedure

Incidence of in-stent thrombosis = number of target aneurysms with parent vessel (in-stent) thrombosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

at 180 days, at 1 year post procedure
Incidence of in-stent stenosis
Časové okno: at 180 days, at 1 year post procedure

Incidence of in-stent stenosis = number of target aneurysms with parent vessel (in-stent) stenosis during follow-up ÷ total number of target aneurysms receiving follow-up ×100%.

Mild, moderate, and severe in-stent stenosis is clinically defined as a stenosis of <33%, 33-67%, and ≥67%, respectively, comparing with non-stented parent vessel [43, 44]. In this study, moderate and severe in-stent stenoses (with a stenosis of ≥33%) of the parent vessel are defined as in-stent stenosis.

at 180 days, at 1 year post procedure

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Xinjian Yang, Professor, Beijing Tiantan Hospital
  • Vrchní vyšetřovatel: Shiqing Mu, Professor, Beijing Tiantan Hospital
  • Vrchní vyšetřovatel: Qingrong Zhang, Professor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  • Vrchní vyšetřovatel: Yuxiang Gu, Professor, Huashan Hospital Shanghai Medical college, Fudan University
  • Vrchní vyšetřovatel: Chuanzhi Duan, Professor, Southern Medical University, China
  • Vrchní vyšetřovatel: Shu Wan, Professor, Zhejiang Hospital
  • Vrchní vyšetřovatel: Bo Yu, Professor, Shengjing Hospital
  • Vrchní vyšetřovatel: Yang Wang, Professor, The First Affiliated Hospital of Nanchang University
  • Vrchní vyšetřovatel: Sheng Guan, Professor, The First Affiliated Hospital of Zhengzhou University
  • Vrchní vyšetřovatel: Wohua Zhao, Professor, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
  • Vrchní vyšetřovatel: Xinjian Yang, Professor, Beijing Anzhen Hospital

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

30. července 2020

Primární dokončení (Aktuální)

22. dubna 2022

Dokončení studie (Aktuální)

26. července 2026

Termíny zápisu do studia

První předloženo

27. února 2020

První předloženo, které splnilo kritéria kontroly kvality

27. února 2020

První zveřejněno (Aktuální)

28. února 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

4. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • CNV_2018_02

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Johnson & Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ano

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .